IO102-IO103 is an investigational immune-modulating therapeutic cancer vaccine designed to target immunosuppressive mechanisms.
Metastatic melanoma is a life-threatening cancer and although many new treatments have been introduced over the last decade that have significantly improved the outcomes for patients, there remains a high unmet need for more efficacious options with low treatment-induced toxicity.
“Completion of enrollment in this pivotal phase 3 trial marks a significant milestone for our company and is a testament to the enthusiasm for this study among our investigators and the patient community,” said Mai-Britt Zocca, CEO and president of IO Biotech.
“We would like to extend our gratitude to the patients, caregivers, investigators, and study staff whose commitment to this trial is helping bring us closer to potentially changing the treatment paradigm for patients with advanced melanoma.”
Patients for the upcoming trial, conducted in collaboration with Merck, have been enrolled from centers across the United States, Europe, Australia, Turkey, Israel and South Africa.
The primary endpoint of the study is progression free survival and biomarker analyses will also be completed.
Andrew Poklepovic, principal investigator at the VCU Massey Comprehensive Cancer Center in Richmond, Virginia, commented: “I am very excited to see the successful completion of accrual to this important Phase 3 trial and eagerly await reported outcomes.”
“The phase 1/2 trial previously reported showed outstanding preliminary data on efficacy and safety. Phase 3 validation of this novel immune modulatory approach combined with standard of care anti-PD-1 has the potential to transform the field of melanoma and illuminate new ways to approach the treatment of cancers with immunotherapy.”
